La vendita allo scoperto per Mangoceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Mangoceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Mangoceuticals (NASDAQ:MGRX) Azioni, Report sulle vendite allo scoperto

Mangoceuticals

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Mangoceuticals Inc

Most Americans think they're playing it smart with credit cards—earning points here, dodging interest there. But when Tucker Carlson asked financial guru Dave Ramsey a simple question—"What's wrong with having a credit card if you pay the balance every month?"—he didn't expect the answer to unravel a myth baked into American consumer habits.
"Most people don't," Ramsey replied. "That's the great lie." He added, "Everybody talks about this theoretical discipline that they just freaking don't have."
It wasn't just a hot take—it was backed by data. "78% roll the balance over month to month," Ramsey said. "Just like 97% of the people don't pay a 30-year mortgage like a 15."
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Carlson, who invited Ramsey onto <a href="https://youtu.be/KwZG7QlfVe8?si=A-nxr_wTtHqgNEd3">"The Tucker Carlson Show" last October</a>, seemed genuinely surprised. But Ramsey wasn't finished. He pointed to the emotional grip credit cards have on Americans. "People have physical reactions when they cut up their credit cards. I mean they're—they're crying, they're shaking."
Ramsey, who built a financial empire around the idea of living debt-free, doesn't own a single credit card. "I don't have credit cards. I haven't, you know, in 30-something years," he said. "I have debit cards on my business and debit cards on my personal account, and I use it like most people use a credit card."
He argued debit cards do everything credit cards do—just without the risk. "If you're going to <a href="https://www.benzinga.com/personal-finance/management/25/06/45779656/a-couple-followed-dave-ramsey-and-got-out-of-debt-then-they-took-a-hard-turn-and-ended-up-46000-in-the-red-on-13-credit-cards">pay your credit card off</a> every month and you're really going to do that, then a debit card will work… it's the exact same freaking thing."
But for most people, it doesn't play out that way. "The average American right now is $37,000 in credit card debt," Ramsey said. "They charge 18 to 28%… so you run that out times 300 million and you've got some money coming into good old Chase."
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
When Carlson asked why credit card companies seem untouchable—never facing backlash the way banks, corporations, or politicians do—Ramsey pointed to marketing. "We're taught again with the most repetitive sophisticated marketing over the longest period of time in human history… we've been taught don't leave home without it."
He called the messaging so effective it's become something of a religion. "It's an altar that we worship at," Ramsey said. "And it's not."
He even took aim at people who claim to be making money with cards. "People with a master's degree in finance: ‘I got 1% back on my Discover card.' So you're going to run 100 grand through your Discover card to get $1,000 back. On what planet does that build wealth?"
Carlson laughed but stayed focused. "So you're just saying, your argument is they're just too dangerous."
"It's not even that it's that dangerous. If you are paying it off every month, it's not going to bankrupt you," Ramsey said. But even then, he warned, the psychological impact of using plastic changes how people spend.
"When you swipe plastic, you spend 12 to 18% more than if you lay down actual cash," he said, <a href="https://mitsloan.mit.edu/press/mit-sloan-study-shows-credit-cards-act-to-step-gas-to-increase-spending">citing an MIT study</a>. "Because cash, when you see Benjamin looking at you, activates the pain center of the brain."
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
With cards—or worse, Apple Pay—there's no mental friction. "You just moved your phone around like you just returned an email or a text and now you're walking out of Home Depot with another tool."
Even the way stores hand back your card tricks the brain. "When you hand someone a piece of plastic at the store, they hand you the groceries or the shirt back with the plastic," he said. "When you hand them money, they just hand you the shirt."
Ramsey and his wife still pay for groceries in cash. "Sharon still carries an envelope with cash in it in her purse for—it says groceries on it," he said.
Despite the <a href="https://www.benzinga.com/25/05/45297103/a-dave-ramsey-fan-explains-how-they-feel-free-after-cutting-every-credit-card-im-tired-of-managing-payments-every-month">cultural dependence on cards</a>, Ramsey says it doesn't have to be that way. Debit cards work for car rentals and hotel bookings, and fraud protection exists for both. "You actually have to have money in your freaking account in order to spend it," he said.
To him, the risks, the habits, and the industry profits all add up to one conclusion: "There's no point."
Read Next: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Image: Shutterstock

Personal Finance

Tucker Carlson Asks Dave Ramsey Why Credit Cards Are a Problem If You Pay Them Off — Ramsey Says, 'That's the Great Lie… Most People Don't'

Truist Securities analyst Brandon King maintains Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Buy and raises the price target from $92 to $96.

News

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Western Alliance, Raises Price Target to $96

Wells Fargo analyst Michael Brown maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Underweight and raises the price target from $55 to $57.

Wells Fargo Maintains Underweight on Brookfield Asset Mgmt, Raises Price Target to $57

Truist Securities analyst Brian Foran maintains UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Buy and raises the price target from $120 to $128.

UMBF

Truist Securities Maintains Buy on UMB Financial, Raises Price Target to $128

GLBKV

Trading Halt: Halt status updated at 9:40:00 AM ET: Quotation Resumption: New Issue Available

GLBAV

Trading Halt: Halt status updated at 9:40:02 AM ET: Quotation Resumption: New Issue Available

Wells Fargo analyst Michael Brown maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Equal-Weight and raises the price target from $153 to $167.

Wells Fargo Maintains Equal-Weight on Blackstone, Raises Price Target to $167

Wells Fargo analyst Michael Brown maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Overweight and raises the price target from $189 to $202.

ARES

Wells Fargo Maintains Overweight on Ares Management, Raises Price Target to $202

Wells Fargo analyst Michael Brown maintains Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Overweight and raises the price target from $160 to $173.

Wells Fargo Maintains Overweight on Apollo Asset Management, Raises Price Target to $173

Milestone&#xAE; Pharmaceuticals Inc. ("Milestone") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the "Offering") of (i) 31,500,000 of its common shares (the "Shares"), accompanying Series A common warrants (the "Series A Common Warrants") to purchase an aggregate of 31,500,000 common shares and accompanying Series B common warrants (the "Series B Common Warrants") to purchase an aggregate of 31,500,000 common shares , at a combined public offering price of $1.50 per share and accompanying Series A Common Warrant and Series B Common Warrant and (ii) in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase 3,502,335 common shares, accompanying Series A Common Warrants to purchase an aggregate of 3,502,335 common shares and accompanying Series B Common Warrants to purchase an aggregate of 3,502,335 common shares, at a combined public offering price of $1.499 per pre-funded warrant and accompanying Series A Common Warrant and Series B Common Warrant, which represents the combined public offering price for the Shares and accompanying common warrants less the $0.001 per share exercise price for each such pre-funded warrant. The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $52.5 million. The Offering is expected to close on or about July 14, 2025, subject to satisfaction of customary closing conditions.
Milestone intends to use the net proceeds from the Offering together with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead indication of paroxysmal supraventricular tachycardia (PSVT), as well as for working capital and other general corporate purposes.

MIST

Milestone Pharma Prices $52.5M Equity Offering With Warrants; Offering Is Expected To Close On Or About July 14, 2025

Wells Fargo analyst Ike Boruchow maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Overweight and raises the price target from $22 to $25.

LEVI

Wells Fargo Maintains Overweight on Levi Strauss, Raises Price Target to $25

<a href="https://www.bloomberg.com/news/articles/2025-07-11/delta-strips-engines-off-new-airbus-jets-to-overcome-shortage?srnd=phx-economics-v2" title="https://www.bloomberg.com/news/articles/2025-07-11/delta-strips-engines-off-new-airbus-jets-to-overcome-shortage?srnd=phx-economics-v2">https://www.bloomberg.com/news/articles/2025-07-11/delta-strips-engines-off-new-airbus-jets-to-overcome-shortage?srnd=phx-economics-v2</a>

'Delta Strips Engines Off New Airbus Jets To Overcome US Shortage' - Bloomberg

United States Cellular Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) and Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) report that the US Department of Justice Antitrust Division announced yesterday that it has closed its investigation into the proposed transaction with T-Mobile. The transaction remains subject to approval by the Federal Communications Commission (FCC), and we continue to work with the FCC as they complete their independent assessment.

United States Cellular And Telephone And Data Systems Say US Department Of Justice Antitrust Division Closes Investigation Into Proposed Transaction With T-Mobile

Truist Securities analyst David Smith maintains Synovus Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Buy and raises the price target from $56 to $60.

Truist Securities Maintains Buy on Synovus Financial, Raises Price Target to $60

Wells Fargo analyst Stephen Baxter downgrades Oscar Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) from Equal-Weight to Underweight and lowers the price target from $16 to $10.

Downgrades

OSCR

Wells Fargo Downgrades Oscar Health to Underweight, Lowers Price Target to $10

Truist Securities analyst Brandon King maintains Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) with a Buy and raises the price target from $123 to $127.

PNFP

Truist Securities Maintains Buy on Pinnacle Finl Partners, Raises Price Target to $127

UBS analyst Joshua Spector downgrades Albemarle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) from Neutral to Sell and lowers the price target from $64 to $57.

UBS Downgrades Albemarle to Sell, Lowers Price Target to $57

Truist Securities analyst Brian Foran maintains Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) with a Buy and raises the price target from $26 to $27.

Truist Securities Maintains Buy on Old National, Raises Price Target to $27

General

ALTI

AlTi Global To Wind Down Non-Core International Real Estate Business

Truist Securities analyst David Smith maintains F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) with a Buy and raises the price target from $16.5 to $17.5.

Truist Securities Maintains Buy on F N B, Raises Price Target to $17.5

Press Releases

Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research

Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution

Mangoceuticals Announces the Launch of "PeachesRx" - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments

Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada

CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

MGRX

UPXI

Guardian Pharmacy Services, Inc. Class A Common Stock

Guardian Pharmacy Service

Ridgetech

Walgreens Boots Alliance, Inc. - Common Stock

Walgreens Boots Alliance

Screenshot 2024-09-25 at 8.34.28 PM

Health Care

Interview

Men&#39;s Telehealth Company&#39;s Plans To Change Men&#39;s Wellness

Screenshot 2024-09-04 at 5.36.44 PM

Biotech

Hims & Hers Health, Inc. Class A Common Stock

Comments

Mangoceuticals

Vendite allo scoperto

Mangoceuticals (NASDAQ:MGRX) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO